![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.155 | 3.43% | 4.675 | 4.35 | 5.00 | - | 25,623 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/8/2020 07:56 | Joe it will come 😎 | ![]() d1nga | |
28/8/2020 07:54 | these papers are all very well, but I - like I'm sure most s'holders - would like to see a positive application of them through further progression/approval | ![]() sloppyjoe2 | |
28/8/2020 07:47 | Fauci seems to be a strong advocate of early intervention in C-19. I wonder if he’s been in contact with Holgate? | ![]() wetdream | |
28/8/2020 07:38 | All the above papers are from the last 24hrs. | ![]() waterloo01 | |
28/8/2020 07:37 | Yet another positive paper. Don't give up just before the finish! Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison Notably, higher IFN-λ levels in COVID-19 patients correlate with lower viral load in bronchial aspirates and faster viral clearance, and a higher IFN-λ:type I IFN ratio with improved outcome of critically ill patients. Moreover, altered cytokine patterns in COVID-19 patients correlate with longer hospitalization time and higher incidence of critical disease and mortality compared to flu. These data point to an untuned antiviral response in COVID-19 contributing to persistent viral presence, hyperinflammation and respiratory failure. | ![]() waterloo01 | |
28/8/2020 07:36 | Thanks to makendon Indeed, many companies that have found they can apply IP and business capacity to fighting the virus have seen their share prices rocket – UK small-cap Synairgen, for instance, saw its shares soar more than 1000% between the start of the year and mid-April as investors piled in on its plans to develop a potential treatment for coronavirus. Nevertheless, while some valuations in the US might have edged too high, in the UK that certainly is not yet the case. Indeed, we are currently seeing a trend of US institutional investors coming in to buy what they see as undervalued UK biotech companies. | ![]() waterloo01 | |
28/8/2020 07:31 | SNG just too risky. Took profits and moved into DNL a few weeks ago. Much more upside potential there IMHO. | walkermike1 | |
28/8/2020 07:28 | I take no pleasure in being right this morning. | ![]() sloppyjoe2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions